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Abstract
Background: Eradication rates of standard triple therapy for Helicobacter pylori infections have decreased in recent
years due to a worldwide increase in bacterial resistance. Sequential therapy has the advantage of a two-phase
treatment regimen and achieves a superior result for H. pylori eradication in peptic ulcer disease. However, no
study has yet compared the efficacy of sequential therapy for H. pylori eradication exclusively in inactive duodenal ulcer
(iDU) or non-ulcer dyspepsia (NUD).
Method: We retrospectively recruited 408 patients with endoscopic proven iDU (170 patients) or NUD (238 patients)
infected with H. pylori. Patients with iDU were assigned into two groups: iDU triple therapy group, 44 patients treated
with 40 mg pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days; iDU sequential
therapy group, 126 patients treated with 40 mg pantoprazole and 1000 mg amoxicillin, twice daily for the first 5 days,
followed by 40 mg pantoprazole, 500 mg clarithromycin and 500 mg tinidazole, twice daily for the next 5 days. All
patients with NUD were treated with sequential therapy and assigned as the NUD sequential group. Post-treatment
H. pylori status was confirmed by a 13C-urea breath test.
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Result: The eradication rates of intention-to-treat (ITT) and per-protocol (PP) analysis were 77.3 % (95 % CI 64.9–89.7 %)
and 85.0 % (95 % CI 73.9–96.1 %) in the iDU triple therapy group and 87.3 % (95 % CI 81.5–93.1 %) and 92.4 % (95 % CI
87.6–97.2 %) in the iDU sequential therapy group. The overall eradication efficacy was superior in the sequential group
than in the triple group, both with ITT analysis (83.5 % vs. 77.3 %, P = 0.29) and PP analysis (88.1 % vs. 85.0 %, P = 0.57).
Eradication rates for ITT and PP analysis were 81.5 % (95 % CI 76.6–86.4 %) and 85.8 % (95 % CI 83.5–88.2 %) in the
NUD sequential therapy group. Eradication rate was statistically better in the iDU sequential therapy group than the
NUD sequential therapy group according to per protocol analysis (P = 0.04). Eradication rate was not significantly
different between the iDU sequential- and iDU triple therapy groups according to protocol analysis (P = 0.14).
Conclusion: The sequential regimen has a better eradiation rate in the iDU group than in the NUD group. There is no
statistically difference between 10-day sequential therapy and 7-day standard triple in iDU group.
Keywords: Helicobacter pylori, Inactive Duodenal ulcer, Non-ulcer dyspepsia, Sequential therapy, Triple therapy
Background
Helicobacter pylori (H. pylori) has been proved to be a
major cause of chronic gastritis, and peptic ulcer disease
[1, 2]. Furthermore, H. pylori infection is also a crucial
cause of gastric cancer [3, 4] and is associated with an
increased risk of gastric mucosa-associated lymphoid tis-
sue (MALT) lymphoma [5]. WHO has categorized H.
pylori as a class I carcinogenic agent in humans; there-
fore, its eradication has been an important step in the
treatment of peptic ulcer disease and prevention of gas-
tric malignancy [6–8].
Treatment of H. pylori has been evolving rapidly over
the past two decades and several regimens have been
proposed to maintain or even increase eradication rates.
When first introduced, the now standard triple therapy
using proton pump inhibitors, amoxicillin, and clarithro-
mycin, was popular and recommended as first-line ther-
apy for H. pylori in Asia and other regions of the world
[7–9]. The eradication rates of this regimen, however,
have declined below 80 % as observed in many of the
latest studies because of increasing drug resistance,
mostly to clarithromycin [10–12]. Several approaches
have been proposed to overcome the low eradication
rates. Sequential therapy was first proposed by Zullo
et al, in Italy [13]. This two-phase treatment regimen,
which involves a proton pump inhibitor plus amoxi-
cillin for the first 5 days followed by a proton pump
inhibitor plus clarithromycin and tinidazole or metro-
nidazole for a further 5 days, achieved better results
than standard triple therapy [14–16].
Many studies have proved that successful eradication
of H. pylori substantially reduces the recurrent rate of
duodenal ulcers [17, 18] and its recommendation has a
worldwide consensus [7–9]. However, no study has yet
demonstrated the efficacy of sequential therapy for
H. pylori eradication exclusively in an inactive duodenal
ulcer (iDU). On the other hand, a significant portion of
non-ulcer dyspepsia (NUD) patients are infected with
H. pylori [19] and its eradication improved dyspeptic
symptoms. [20] An early study, which compared triple
therapy with ranitidine bismuth citrate based quadruple
therapy in treatments between peptic ulcer disease
(PUD) and NUD patients, revealed better eradication re-
sults in PUD [21]. With a similar regimen in another
study, there was no convincing evidence to imply that
NUD patients responded to H. pylori eradication treat-
ments differently from those with PUD [22].
The aim of our study was to compare the efficacy of
currently used two-phase sequential therapy with stand-
ard triple therapy for H. pylori eradication in patients
with iDU and the efficiency of sequential therapy in iDU
and NUD in the Taiwanese population.
Methods
Study population and intervention
We enrolled consecutive patients with endoscopically
proven iDU or NUD who were infected with H. pylori,
which is defined as a positive rapid urease test (CLOtest;
Kimbery-Clark, Roswell, GA 30076 USA) from the
gastroenterology clinic in one medical center in Taipei,
Taiwan. All patients were >18 years of age and had never
received treatment for H. pylori. Additional exclusion
criteria included: (i) consumption of antibiotics, non-
steroid anti-inflammatory drugs, proton pump inhibitors
(PPI), H2-receptor antagonists, or bismuth salt during
the previous four weeks; (ii) allergy or contraindications
to antibiotics or PPI; (iii) previous gastric surgery; (iv)
severe concomitant cardiopulmonary disease or serious
hepatic/renal dysfunction or malignancy; and (v) preg-
nancy or lactation.
Patients received esophagogastroduodenoscopy (EGD;
Olympus, GIF-XP 260) before enrolment to determine
iDU or NUD. The study was approved by the Institu-
tional Review Board of the Cathy General Hospital. The
trial registration number is CGH-P104077, and the
registration date is September 30,2015. Informed con-
sent was obtatined from all patients before EGD.
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Patient selection and H. pylori detection
An inactive duodenal ulcer was defined as an endo-
scopic inspection of a white scar longer than 3 mm
with converging folds, located over the duodenal bulb
region. Patients with findings of coexisting active ulcers
were excluded. Non-ulcer dyspepsia patients were de-
fined as having clinical symptoms of persistent pain or
discomfort focused over the epigastric region for at
least one month and no abnormality could be detected
during endoscopic inspection or during a normal ab-
dominal ultrasound examination. One biopsy specimen
was obtained from at least 2 cm away from the pylorus
along the greater curvature side of the antrum for a
rapid urea test. H. pylori infection was diagnosed if the
rapid urea test was positive.
Therapy protocol
Patients with iDU were assigned into 2 groups accord-
ing to a physician’s discretion: the iDU triple therapy
group (hereafter, the iDU triple group) contained 44 pa-
tients who received a triple therapy regimen: 40 mg
pantoprazole, 1000 mg amoxicillin, and 500 mg clari-
thromycin, twice daily for 7 days. The iDU sequential
therapy group (hereafter, the iDU sequential group)
contained 126 patients and they received a sequential
therapy regimen: 40 mg pantoprazole and 1000 mg
amoxicillin, twice daily for the first 5 days, followed by
40 mg pantoprazole, 500 mg clarithromycin and
500 mg tinidazole, twice daily for the next 5 days. All
238 patients with NUD were treated with a sequential
therapy regimen and assigned to the NUD sequential
group.
Post treatment measurement
Results of H. pylori status after eradication therapy
were determined using a 13C-urea breath test (13C-UBT).
When patients had persistent epigastric symptoms,
follow-up endoscopy was performed to make sure
there were no newly developed lesions. Assessment of
H. pylori status again used a rapid urease test (CLO).
The 13C-UBTs were performed at least 2 months
apart and from the date at the end of therapy. The
UBT was performed after an overnight fast. A base-
line breath sample was obtained and then 75 mg of
13C urea with 1.5 g of citric acid was administered as
an aqueous solution. The second breath sample was
collected 30 min after the intake of test solution. The
result was defined positive if the difference between
the baseline sample and the 30-min sample exceeded
4.5 per mil of 13CO2. The sensitivity and specificity
values of the UBT were reported as 94.7 % and
95.7 %, respectively [23]. Therapy compliance and
drug adverse effects were assessed by personal inter-
view after the end of treatment.
Statistical analysis
We used intention-to-treat (ITT) and per-protocol (PP)
analysis in assessment of the eradication efficacy. En-
rolled eligible patients who started medication were all
included in the ITT analysis regardless of the correct
protocol or compliance. Patients who did not take at
least 80 % of the medication or who had incomplete
treatment were excluded from PP analysis.
We compared continuous variables with the Student’s
test and presented an arithmetic mean and standard de-
viations. Qualitative variables were analyzed with the
chi-square test and presented as percentage and 95 %
confidence intervals (95 % CI). All statistical tests were
two-sided and all P values <0.05 were considered statis-
tically significant. The analyses were performed using




From September 2007 to June 2010, we recruited 408
patients with endoscopic proven iDU or NUD and who
were infected with H. pylori. Figure 1 shows the flow
diagram of patients during the protocol. A total of 170
patients were diagnosed as iDU patients and 238 pa-
tients were diagnosed as NUD patients. Of the 170 iDU
patients, 126 were assigned to the iDU sequential group
and the remaining 44 patients were assigned to the iDU
triple group. All 238 NUD patients were assigned to the
NUD sequential group. Patients of these 3 groups all
went through the complete protocol and 7 patients
(5.6 %), 4 patients (9.1 %), and 12 patients (5.0 %) of the
iDU sequential group, iDU triple group, and NUD se-
quential group, respectively, did not take the complete
regimen of medication. Comparison of clinical character-
istics and eradication rates between the iDU sequential
group vs. the iDU triple group and the iDU sequential
group vs. the NUD sequential group were performed with
both ITT and PP analysis.
Eradication rates of H. pylori
Demographic characteristics of the sequential and triple
groups are summarized in Table 1. A total of 364 pa-
tients (126 of iDU patients and 238 of NUD patients)
received the sequential regimen; mean age was 51.0 ±
11.2 y and females were dominant. Forty-four patients
received conventional triple therapy; mean age was
52.6 ± 9.5 y and females were dominant. The eradica-
tion efficacy was better in the sequential group than in
the triple group, both with ITT analysis (83.5 % vs.
77.3 %) and PP analysis (88.1 % vs. 85.0 %). Neither
analysis, however, demonstrated a significant difference
in the 2 therapy regimens.
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Demographic characteristics and eradication rate of
the iDU sequential group vs. the iDU triple group are
summarized in Table 2. Females were more dominant in
the iDU triple group than in the iDU sequential group.
Age was similar between these two groups. The eradica-
tion rate of ITT and PP analyses were 77.3 % (95 % CI
64.9–89.7 %) and 85.0 % (95 % CI 73.9–96.1 %) in the
iDU triple group and 87.3 % (95 % CI 81.5–93.1 %) and
92.4 % (95 % CI 87.6–97.2 %) in the iDU sequential
group. The eradication rate of H. pylori in the iDU se-
quential group was better than in the iDU triple group
both with ITT and PP analyses. However, the differences
were not significant and P values were 0.22 and 0.14,
respectively.
Demographic characteristics and eradication rate of the
iDU sequential group vs. the NUD sequential group are
Fig. 1 Trial flowchart scheme
Table 1 Baseline demographic and clinical characteristics of the patients
ITT PP
Triple therapy Sequential therapy Triple therapy Sequential therapy
Number of patients 44 364 40 345
Age (Mean ± SD) 52.6 ± 9.5 51.0 ± 11.2 53.7 ± 9.0 51.1 ± 11.2
Gender (%)
Male 9 (20.5 %) 135 (37.1 %) 7 (17.5 %) 127 (36.8 %)
Female 35 (79.5 %) 229 (62.9 %) 33 (82.5 %) 218 (63.2 %)
Endoscopic finding
iDU 44 (100 %) 126 (34.6 %)
NUD 238 (65.4 %)
Eradication success 34 304 34 304
Eradication rate 77.3 % 83.5 % 85.0 % 88.1 %
95 % CI 64.9–89.7 % 79.9–87.3 % 73.9–96.1 % 84.7–91.5 %
P-value 0.29 0.57
ITT intention to treat, PP per protocol
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summarized in Table 3. Females were more dominant in
the NUD sequential group than in the iDU sequential
group. Age was similar between these two groups. The
eradication rate of ITT and PP analyses were 87.3 % (95 %
CI 81.5–93.1 %) and 92.4 % (95 % CI 88.4–96.4 %) in the
iDU sequential group and 81.5 % (95 % CI 76.6–86.4 %)
and 85.8 % (95 % CI 83.5–88.2 %) in the NUD sequential
group. The eradication rate of H. pylori in the iDU se-
quential group was better than in the NUD sequential
group both for ITT and PP analyses. Difference was sig-
nificant in PP analysis but not so marked in ITT analysis;
P values were 0.04 and 0.11 respectively.
Adverse events and compliance
Table 4 shows the adverse events and their incidences
in conventional triple and sequential therapy groups.
The overall adverse event rate was higher in the se-
quential group than in the triple group (36.3 % vs.
22.7 %, P = 0.08). The highest incidence of adverse
events was mouth bitterness in both groups. Patients
reported compliances were similar in both the triple
and sequential groups (90.9 % vs. 94.8 %, P = 0.29).
Discussion
Standard triple therapy, when first proposed, was dem-
onstrated to have a high eradication efficacy with a suc-
cess rate over 85 % [24]. Therefore, most therapeutic
guidelines from major academic committees worldwide
recommended a proton pump inhibitor based triple
therapy plus clarithromycin and amoxicillin or metro-
nidazole as the first-line regimen for eradication of H.
pylori [7–9]. Unfortunately, the eradication rate of this
gold standard therapy declined rapidly during the fol-
lowing 10 years toward unacceptable levels [25]. The
frustrating outcome of the poor eradication rate led to
several new strategies aimed to raise eradication effi-
cacy. Innovative therapeutic approaches included ex-
tending therapy duration, the altering of conventionally
used antibiotics to novel ones, and the addition of
multi-drug regimens.
Table 2 Characteristics of subjects in ITT and PP and a comparison of the eradication rate between iDU triple and iDU sequential
groups
ITT PP
iDU triple iDU sequential iDU triple iDU sequential
Number of patients 44 126 40 119
Gender (%)
Male 9 (20.5 %) 57 (45.2 %) 7 (17.5 %) 52 (43.7 %)
Female 35 (79.5 %) 69 (54.8 %) 33 (82.5 %) 67 (56.3 %)
Age (Mean ± SD) 52.6 ± 9.5 52.4 ± 12.3 53.7 ± 9.0 52.4 ± 12.3
Eradication success 34 110 34 110
Eradication rate 77.3 % 87.3 % 85.0 % 92.4 %
95 % CI 64.9–89.7 % 81.5–93.1 % 73.9–96.1 % 87.6–97.2 %
P-value 0.22 0.14
ITT intention to treat, PP per protocol, iDU inactive duodenal ulcer
Table 3 Characteristics of subjects in ITT and PP and a comparison of the eradication rate between iDU sequential and NUD
sequential groups
ITT PP
iDU Sequential NUD Sequential iD U Sequential NUD Sequential
Number of patients 126 238 119 226
Gender (%)
Male 57 (45.2 %) 78 (32.8 %) 52 (43.7 %) 75 (33.2 %)
Female 69 (54.8 %) 160 (67.2 %) 67 (56.3 %) 151 (66.8 %)
Age (Mean ± SD) 52.4 ± 12.3 50.3 ± 10.7 52.4 ± 12.3 50.4 ± 10.6
Eradication success 110 194 110 194
Eradication rate 87.3 % 81.5 % 92.4 % 85.80 %
95 % CI 81.5–93.1 % 76.6–86.4 % 88.4–96.4 % 83.5–88.2 %
P-value 0.11 0.04
ITT intention to treat, PP per protocol, iDU inactive duodenal ulcer, NUD non-ulcer dyspepsia
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A two-phase sequential regimen, by adding a fourth
drug, has been shown to have promising eradication re-
sults in many studies worldwide. However, most of these
trials were conducted in patients diagnosed with H. pyl-
ori infection and without separately analyzed eradication
rates in either ulcer related or non-ulcer related groups.
Our current work was a trial to compare the eradication
efficacy of sequential therapy and conventional triple
therapy exclusively in inactive duodenal ulcer and non-
ulcer dyspepsia patients. The results demonstrated that a
10-day sequential regimen was superior to conventional
triple therapy for eradication of H. pylori in treatment
naïve patients. Overall, the eradication rate of sequential
therapy was 88.1 % with PP analysis and 83.5 % with
ITT analysis, which were higher than those of triple
therapy (85.0 % with PP analysis and 77.3 % with ITT
analysis). The result is similar to that shown in other
studies in Western and Asian countries [26–31]. How-
ever, in our trial, the eradication rate of sequential ther-
apy did not reach the good category according to the
Graham’s report card for grading H. pylori therapy [32]
(90–95 % intention-to-treat) as with most other studies
[15, 33, 34] and did not demonstrate a significant differ-
ence compared to triple therapy. One randomized con-
trolled trial in southern Taiwan reported a high
eradication rate (92.9 % with PP and 93.2 % with ITT
analysis) of sequential therapy [35]. Patients they en-
rolled had either gastric ulcers or duodenal ulcers
(94.3 % of total patients). We suggest the reason why
our results did not yield a higher eradication efficacy
may be due to the type of gastroduodenal diseases in
our patients. Our patient pool only consisted of either
inactive duodenal ulcer or non-ulcer dyspepsia patients.
Previous studies found that the eradication rate of
standard triple therapy in non-ulcer dyspepsia tends to
be lower than that in peptic-ulcer patients [21, 36]. Con-
trary results are observed in sequential therapy and the
success rates are not significantly affected by patho-
logical findings (peptic-ulcer vs. non-ulcer dyspepsia)
[37, 38]. Our study’s result was different, in that the
eradication rate of sequential therapy (Table 3) was bet-
ter in duodenal ulcer scar patients than in non-ulcer
dyspepsia with ITT analysis (87.3 % vs. 81.5 %) and with
PP analysis (92.4 % vs. 85.8 %), which reached a signifi-
cant difference. Two large studies (DU-MACH [39] and
GU-MACH [40]) have therefore looked at the impact of
inflammation on H. pylori eradication. Polymorph infil-
tration in the antrum of patients with inflammation of
grades 2/3 was associated with a significantly higher
eradication rate when compared with inflammation of
grades 0/1. Previous ulcer diseases may induce inflam-
mation processes that cause degradation of the mucus
and epithelial layers and altered epithelial permeability.
That may allow better penetration of antibiotics from
the gastric lumen and better systemic delivery of drugs.
Besides, the subtype of H. Pylori that cause ulcer may be
more aggressive which has a better response to the anti-
biotics. Therefore, we speculate that the low eradication
rate of sequential therapy in non-ulcer dyspepsia pa-
tients tarnished the overall eradication rate of sequen-
tial therapy in our 364 patients with either duodenal
ulcer scar or non-ulcer dyspepsia. Although eradication
of Helicobacter Pylori is both suggested in patient with
duodenal ulcer scar or non-ulcer dyspepsia, the differ-
ence in eradication rate could provide us a better out-
come predication to discuss with the patient.
Although the difference was not statistically signifi-
cant, subgroup analysis revealed a superior eradication
rate of sequential therapy in duodenal ulcer scar patients
(Table 2; ITT, 87.3 % vs. 77.3 %; PP, 92.4 % vs. 85.0 %).
Table 4 Adverse events in sequential therapy
Triple iDU Sequential NUD Sequential Total Sequential
Adverse event (N = 44) (N = 126) (N = 238) (N = 364)
Taste disturbance 6.8 % 7.10 % 7.60 % 7.40 %
Diarrhea 0.0 % 2.40 % 0.40 % 1.10 %
Abdominal discomfort 0.0 % 3.20 % 0.40 % 1.40 %
Skin rash 0.0 % 1.60 % 0.80 % 1.10 %
Nausea 2.3 % 0.00 % 0.80 % 0.50 %
Poor appetite 0.0 % 0.00 % 0.40 % 0.30 %
Dizziness 0.0 % 2.40 % 0.40 % 1.10 %
Mouth bitterness 11.4 % 28.60 % 11.30 % 17.30 %
Loose stool 2.3 % 3.20 % 7.10 % 5.80 %
Cramp 0.0 % 0.80 % 0.00 % 0.30 %
Total 22.7 % 49.20 % 29.40 % 36.30 %
P value (triple vs total sequential) 0.08
iDU inactive duodenal ulcer, NUD non-ulcer dyspepsia
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Sequential therapy also achieved the acceptable ef-
fectiveness category (86–89 %, ITT) and was better
than triple therapy (unacceptable category: <80 %,
ITT) according to Graham’s category [32]. Since
many studies have proved that successful eradication
of H. pylori substantially reduces the recurrent rate
of duodenal ulcers, it is recommended by a world-
wide consensus. We believe that a 10-day sequential
regimen could be a valid alternative therapy in initial
treatment for the eradication of H. pylori in duodenal
ulcer scar patients.
Our data showed that the overall adverse event rate
was higher in the sequential group than that in the
triple group (Table 4; 36.3 % vs. 22.7 %). The highest in-
cidence of adverse events was mouth bitterness in both
groups. The sequential group had an even higher fre-
quency of mouth bitterness. Nonetheless, patient-reported
compliance was similar in both the triple and sequential
therapy groups (90.9 % vs. 94.8 %).
We also performed the multivariate analysis to inves-
tigate the independent factors predicting eradication
failure in this study. Table 5 showed the eradication ef-
ficiency has no relationship with age and gender. Besides,
the successful eradication group has a significantly higher
adverse reaction rate then the failure group. It seemed that
the eradication rate was associated independently with the
different protocol and presence of ulcer scar.
Furthermore, Table 6 shows the cost of each individual
regimen. Clarithromycin was the most expensive drug
and cost $32.30 in the standard triple therapy regimen,
out of a total cost of $51.00. The sequential therapy regi-
men cost only $47.6. Due to the comparative expense of
standard therapy, replacement of it with the less costly
sequential regimen would greatly reduce total treatment
Table 5 Multivariate analysis to investigate the independent factors
Total (N = 408) Eradication failure (N = 70) Eradication success (N = 338) p-value
Age (Mean ± SD) 51.2 ± 11.1 50.7 ± 10.5 51.3 ± 11.1 0.67
Gender (%)
Male 144 22 (31.4 %) 122 (36.1 %) 0.46
Female 264 48 (68.6 %) 216 (63.9 %)
Adverse event (%)
Yes 140 16 (22.9 %) 124 (36.7 %) 0.03
No 268 54 (77.1 %) 214 (63.3 %)
There is no statistically difference between eradication rate, gender, and age. The success group have more adverse event.
iDU Total failure in iDU (N = 26) Failure in Triple (N = 10) Failure in Sequential (N = 16) p-value
Age (Mean ± SD) 51.7 ± 9.7 48.5 ± 7.9 53.7 ± 10.4 0.19
Gender (%)
Male 9 3 (30.0 %) 6 (37.5 %) 0.7
Female 17 7 (70.0 %) 10 (62.5 %)
Adverse event (%)
Yes 10 2 (20.0 %) 8 (50.0 %) 0.13
No 16 8 (80.0 %) 8 (50.0 %)
In iDU group, there is no statistically difference between failure rate, age, gender, and adverse, event.
Sequential Total failure in Sequential (N = 60) Failure in iDU (N = 16) Failure in NUD (N = 44) p-value
Age (Mean ± SD) 51.0 ± 10.9 53.7 ± 10.4 50.0 ± 11.0 0.26
Gender (%)
Male 19 6 (37.5 %) 13 (29.5 %) 0.56
Female 41 10 (62.5 %) 31 (70.5 %)
Adverse event (%)
Yes 14 8 (50.0 %) 6 (13.6 %) 0.003
No 46 8 (50.0 %) 38 (86.4 %)
In sequential group, there is no statistically difference between failure rate, age, and gender. However, the adverse rate is statistically higher
in iDU group.
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costs. This economical consideration also favors the use
of the latter treatment regimen.
The present study had a couple of limitations. Firstly,
that patients were not randomized to receive either
standard triple therapy or 10-day sequential therapy. Pa-
tients with iDU were assigned into 2 groups according
to a physician’s discretion, which may have introduced
selection bias. Therefore, the number in the iDU triple
group was too small. However, all patients were pro-
spectively followed up with a standard protocol and were
well informed about adverse problems and compliance.
Secondly, bacterial culture was not performed in our
protocol, and therefore the effect of antibiotic resistance
was not able to be assessed. However, the resistance
rates of Amoxicillin, Clarithromycin, Metronidazole, and
Tetracycline in Cathy General Hospital are 13.9, 27.8,
19.4, and 0 % respectively.
Conclusion
Despite no statistically significant difference in ITT
patients, 10-day sequential therapy for the eradication
of H. pylori was superior in iDU patients than NUD
patients and it reached a significant eradication effect-
iveness in PP patients. The sequential regimen has a
better eradication rate in the iDU group than in the
NUD group.
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